4.4 Review

Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term

期刊

INTERNAL AND EMERGENCY MEDICINE
卷 13, 期 6, 页码 839-844

出版社

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s11739-018-1907-x

关键词

Pericarditis; Idiopathic recurrent pericarditis; Innate immune system; Autoinflammatory diseases; Anakinra; IL-1 antagonists

资金

  1. Acarpia
  2. Sobi
  3. Lilly
  4. Menarini
  5. Novartis
  6. Acarpia e SOBI
  7. Kiniksa

向作者/读者索取更多资源

In developed countries, more than 80% of cases of acute pericarditis remain without an established diagnosis after a conventional and standard diagnostic approach. These cases are generally labelled as 'idiopathic', i.e. without a known cause. This lack of information is a matter of concern for both patients and clinicians. Some years ago, this term reflected the state of the art of scientific knowledge on the topic. Advances have changed this point of view, in light of available molecular techniques like polymerase chain reaction able to identify viral cardiotropic agents in pericardial fluid and biopsies. Furthermore, the remarkable efficacy of interleukin-1 antagonists, a therapy targeting the innate immune response, suggests clinical and pathogenic similarity between a proportion of patients with idiopathic recurrent pericarditis and classical autoinflammatory diseases. So, it seems useful to discuss the pros and cons of using the term idiopathic in light of the new knowledge.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据